PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
43.33%
Net income growth under 50% of AVXL's 91.89%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.
-26.41%
Negative yoy D&A while AVXL is 29.69%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
-627.56%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
174.63%
SBC growth while AVXL is negative at -97.56%. John Neff would see competitor possibly controlling share issuance more tightly.
-214.26%
Negative yoy working capital usage while AVXL is 127.95%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-295.13%
Negative yoy AP while AVXL is 0.00%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-30.84%
Negative yoy usage while AVXL is 127.95%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
848.72%
Some yoy increase while AVXL is negative at -98.38%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-15.17%
Negative yoy CFO while AVXL is 24.41%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
100.00%
CapEx growth well above AVXL's 100.00%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Growth of 100.00% while AVXL is zero at 0.00%. Bruce Berkowitz sees a moderate difference requiring justification by ROI in these smaller invests.
100.00%
Investing outflow well above AVXL's 100.00%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
-2235.51%
We cut debt repayment yoy while AVXL is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
219.76%
Stock issuance far above AVXL's 235.81%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
No Data
No Data available this quarter, please select a different quarter.